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Methylmalonic aciduria (MMA) cblB type is caused by mutations in the
MMAB gene, which codes for the enzyme adenosine triphosphate (ATP):
cobalamin adenosyltransferase (ATR). This study reports differences in the
metabolic and disease outcomes of two pairs of siblings with MMA cblB
type, respectively harbouring the novel changes p.His183Leu/p.Arg190dup
(P1 and P2) and the previously described mutations p.Ile96Thr/p.Ser174fs
(P3 and P4). Expression analysis showed p.His183Leu and p.Arg190dup to
be destabilizing mutations. Both were associated with reduced ATR stability
and a shorter half-life than wild-type ATR. Analysis of several parameters
related to oxidative stress and mitochondrial function showed an increase in
reactive oxygen species (ROS) content, a decrease in mitochondrial
respiration and changes in mitochondria morphology and structure in
patient-derived fibroblasts compared to control cells. The impairment in
energy production and the presence of oxidative stress and fission of the
mitochondrial reticulum suggested mitochondrial dysfunction in cblB
patients’ fibroblasts. The recovery of mitochondrial function should be a
goal in efforts to improve the clinical outcome of MMA cblB type.
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ATP:cob(I)alamin adenosyltransferase (ATR, E.C.2.
5.1.17) is involved in coenzyme B12 metabolism, con-
verting reduced cob(I)alamin to adenosylcobalamin.
The latter is the active cofactor of methylmalonyl-CoA
mutase (MUT, EC 5.4.99.2), which catalyses the
reversible rearrangement of methylmalonyl-CoA to
succinyl-CoA during the catabolism of branched-chain
amino acids, odd-chain fatty acids and cholesterol.
Mutations in the human MMAB gene coding for ATR
are responsible for methylmalonic aciduria (MMA)
cblB type (OMIM #607568). Patients with MMA cblB
type suffer either a severe, early-onset form of the
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disease, with neonatal ketoacidosis, lethargy, failure to
thrive and encephalopathy, or a milder late-onset form
usually diagnosed during infancy that has a less serious
neurological outcome (1).
To date, 32 different mutations have been identified in
theMMAB gene in cblB patients (HGMD® Professional
Release 2013.4). Several of these have been functionally
analysed and their kinetic parameters determined in
prokaryotic and eukaryotic expression systems. These
studies have revealed the existence of mutants with
reduced substrate and cofactor affinity (p.R191W) (2),
and with negligible activity and presumed instability
in vivo (p.R186W, p.R190H and p.E193K) (3), as well
as destabilizing mutations that retain some residual
activity (4).
Mitochondrial dysfunction is involved in a number of
human genetic diseases, including inherited metabolic
problems (5–7). In MMA, mitochondrial impairment
occurs through the combination of the specific inhibition
of mitochondrial enzymes, the inhibition of respiratory
complexes, transport inhibition, the restriction of certain
substrates for the tricarboxylic acid (TCA) cycle, and
oxidative damage (8, 9). In fact, in MMA, the mitochon-
drial functional impairment observed in different organs
and fibroblasts from patients, and in mouse models, has
been proposed to be partly responsible for increased
intracellular reactive oxygen species (ROS) levels lead-
ing to oxidative stress (7, 9–11). Genes involved in con-
trolling oxidative stress might therefore act as phenotype
modifiers, helping to explain the different disease presen-
tations in patients with identical genotypes, as described
in oxidative phosphorylation (OXPHOS) disorders (12).
The aim of the present study was to determine the
pathogenic mechanisms of action of two new changes,
c.548A>T and c.568_570dup, detected in a patient
identified in an expanded newborn screening program.
Mitochondrial function in cells from two pairs of cblB
siblings harbouring either the new changes, or the pre-
viously described changes c.287T>C and c.584GA was
also examined.
Materials and methods
The patients examined were two sets of siblings (P1 and
P2; P3 and P4). P1 was identified by expanded new-
born screening; a diagnosis of MMA was performed
by gas chromatography-mass spectrometry (GC-MS)
analysis of organic acids in urine. P2 was identi-
fied by the family genetic study and showed a slight
increase in urine methylmalonic acid (Table 1). P3 and
P4 have been previously described (4, 11). Control
fibroblasts (GM09503, GM08680, GM5756, GM8429
and GM5381) were obtained from the NIGMS Human
Genetic Cell Repository (Coriell Institute for Medical
Research, NJ). The present study was approved by the
Ethics Committees of the Universidad Autónoma de
Madrid. Written permission to perform genetic studies
was provided by the patients’ parents.
Human ATR protein and p.H183L (c.548A>T) and
p.R190dup (c.568_570dup) mutants were expressed in
Escherichia coli; the purification, ATR specific activity Ta
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and KM values were assayed as described (4). The
stability of the wild-type and p.H183L and p.R190dup
proteins was measured by incubation at 27∘C or 37∘C.
Soluble supernatants were incubated at 27∘C or 37 ∘C
and aliquots were removed at different times for sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). Immunodetection was performed using
anti-ATR antibody diluted 1:1000 (ProteinTech Group
Inc., Chicago, IL). Mitochondria isolation from fibrob-
lasts was performed using anti-TOM22 MicroBeads
(Miltenyi Biotec, Bergisch Gladbach, Germany).
ROS assays were performed in fibroblasts from three
controls (GM9503, GM8680 and GM5756) and from all
patients, as described (11).
For bioenergetic analysis, control and patient-derived
fibroblasts (5× 104 each) were seeded per well in 24-well
microplates and incubated with Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with glu-
cose or galactose (4.5 g/l, DMEM-Glu or DMEM-Gal)
overnight at 37∘C. Cells were then washed with phos-
phate buffered saline (PBS); 700 μl of DMEM-Glu or
DMEM-Gal without bicarbonate were added and the
plates incubated at 37∘C for 1 h. Modulating compounds
such as oligomycin (OL, 6 μM), carbonyl cyanide
4-(trifluoromethoxy) phenyl-hydrazone (FCCP, 50 μM),
rotenone (RO, 1 μM) and antimycin A (AT, 1 μM) were
used to assess the bioenergetic profile. Oxygen consump-
tion rate (OCR) was measured using a Seahorse XF24
Extracellular Flux Analyser (Seahorse Bioscience,
Billerica, MA). The calibration plate for these com-
pounds was prepared according to the manufacturer’s
protocol.
For mitochondrial morphology, 100,000 fibroblasts
were seeded on a 10mm glass coverslip and incubated
with MEM at 37∘C overnight. Cells were then incubated
with 500 nM Mitotracker® Red CM-H2Ros probe (Life
Technologies, Grand Island, NY) at 37∘C for 40min,
and fixed in 10% formalin at room temperature for
20min. Cells were washed with PBS and mounted
facing downwards in mounting medium on a microscope
slide. Images were taken using an Axiovert200 inverted
microscope (Zeiss, Jena, Germany; magnification ×63)
equipped with a DsRED filter.
For electron microscopy, fibroblasts were fixed for 1 h
in the culture plates with 4% paraformaldehyde and 2%
glutaraldehyde. Pellets were dehydrated and embedded
in Epon resin.
Results
P1, classified as belonging to MMA cblB type by
somatic cell complementation assay, is clinically asymp-
tomatic and follows a disease management plan to
avoid metabolic crises. His sibling, P2, is asymp-
tomatic. Notably, P2-derived fibroblasts showed a
[14C]-propionate uptake incorporation close to normal,
which decreased significantly when subjected to heat
shock at 42∘C (Fig. 1a). The levels of mitochondrial
ATR protein have been assayed and only some traces of
immunoreactive protein could be detected in P1 and P2
patients-derived fibroblasts (data not shown).
(a)
(b)
Fig. 1. [14C]-Propionate incorporation and intracellular ROS content in
control- and patient-derived fibroblasts. (a) [14C]-Propionate incorpo-
ration was performed by incubation of dermal fibroblasts at 37∘C or
42∘C in the absence of hydroxocobalamin (OHCbl) to provide an indi-
rect quantification of adenosyltransferase (ATR) activity. Results are the
means± SD of three independent experiments (*p< 0.05). (b) Intracellu-
lar ROS content of control and patients’ fibroblasts. Cells were incubated
with the H2DCFDA fluorescence probe, and ROS levels assessed by flow
cytometry. The x-axis represents patient cell lines and the y-axis the flu-
orescence levels. Control value was determined as the mean of data from
the three control cell lines. Data are the mean±SD of five independent
experiments, each performed in triplicate. Data were analysed by analy-
sis of variance (anova; using spss software) with Bonferroni correction
(*p< 0.05, **p< 0.01).
Genetic analysis revealed the presence of two
novel mutations in exon 7 in P1 and P2; one exonic
paternal change probably leading to a missense muta-
tion p.H183L (c.548A>T), and one maternal small
in-frame duplication, p.R190dup (c.568_570dup).
Both changes were absent in the Exome Vari-
ant database (evs.gs.washington.edu). They were
classified as ‘probably damaging’ by PolyPhen2 (genet-
ics.bwh.harvard.edu/pph2) and SIFT (sift.jcvi.org/).
No other changes or copy number variations were
found after promoter sequencing and analysis using
a customized high-resolution comparative genomic
hybridization assay (Metaboloarray®, Agilent,
SantaClara, CA) (13).
ATR activity was measured, and the KM for the
substrates, adenosine triphosphate (ATP) and hydrox-
ocobalamin (OHCbl) were determined using E. coli
cell lysates expressing wild-type or mutant pro-
teins. An approximately 75-fold reduction in specific
578
Methylmalonic aciduria cblB type
(a)
(b) (c)
Fig. 2. Bioenergetic profile of control- and patient-derived fibroblasts. (a) The fundamental parameters of mitochondrial function: basal respiration,
adenosine triphosphate (ATP) turnover, proton leak, and maximal respiration, or spare respiratory capacity. (b) and (c) Bioenergetic profile of patients’
and controls’ fibroblasts cultured in two different kinds of media. Cells were incubated with DMEM supplemented with glucose (b) or galactose (c)
and the oxygen consumption rate (OCR) profile in each case after the addition of oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenyl-hydrazone
(FCCP), rotenone and antimycin A was measured. Data are the mean±SD of three independent experiments, each performed in triplicate. Further
analysis to rescue the phenotype after MMAB complementary DNA (cDNA) correction will be performed in the near future.
activity was seen compared to the wild-type in the
crude extract of bacteria expressing p.His183Leu.
The purification yield was ∼100-fold higher for
wild-type vs p.His183Leu. The kinetic data on puri-
fied ATR showed that the p.His183Leu possessed
specific activities indistinguishable within experimental
variation (0.21± 0.01 μmol/mg/min) than the wild type
(0.23± 0.01 μmol/mg/min). The KMATP (5.1± 1.4 μM)
and KM
OHCbl (0.71± 0.56 μM) values for this mutant
were similar to those of wild type (KM
ATP = 6.2± 1.3 μM
and KM
OHCbl = 1.7± 0.4 μM). The p.Arg190dup mutant
did not show detectable activity in crude extracts and
could not be purified.
The relative half-life of p.His183Leu mutant at 37∘C
was ∼50% that of wild-type (2.5 vs 5.4 h). At 27∘C,
however, p.His183Leu showed a marked increase in
stability (7.6 vs 6.1). As expected, the p.Arg190dup was
highly unstable and could not be examined under any
conditions.
Flow cytometry showed a significant increase of ROS
content in P1 cells and a moderate increase in P2 cells
compared to control fibroblasts. P3 cells also showed a
greater increase in ROS content than P4 cells (Fig. 1b).
For bioenergetic profile OL, FCCP, RO and AT were
sequentially added to the cells and the fundamental
parameters of mitochondrial function obtained are rep-
resented in Fig. 2a. O2 consumption by fibroblasts
revealed that cells grown in DMEM-Glu (Fig. 2b) or
DMEM-Gal (Fig. 2c) had similar bioenergetic profiles.
OCR was reduced in all patient-derived fibroblasts incu-
bated in either medium, with a shift observed towards
higher values in control and patient fibroblasts grown in
DMEM-Gal; indeed, these reached control levels in P2
and P4. This shift is due to an increase in the aerobic
production of ATP in the absence of glucose. The basal
respiratory rates were markedly lower in P1-, P2- and
P3-derived fibroblasts compared to controls. The max-
imum OCR after the injection of FCCP into DMEM-Glu
was lower in patients’ fibroblasts (Fig. 2b), and was dou-
bled in all fibroblasts grown in DMEM-Gal (Fig. 2c).
A reduction in OCR was observed after the addition
of OL. The difference between basal OCR levels and
post-OL addition represents the effect of ATP-linked res-
piration. In the DMEM-Glumedium, a fall in ATP-linked
respiration was observed in all patient-derived fibrob-
lasts compared to controls, especially in P1 (Fig. 2b).
In DMEM-Gal, ATP-linked respiration was higher in all
patient-derived fibroblasts, especially in P4 (Fig. 2c).
Marked fission of the mitochondrial reticulum was
seen in all patient-derived fibroblasts, and mitochondria
were seen to gather around the perinuclear area in P3
cells. Compared to controls, a significantly increased
proportion of grain-like structures were seen in P1, P2
and P3 cells and to a lesser extent in P4 (Fig. 3a and
b). In addition, cblB fibroblasts presented a reduced
number of mitochondria and had a distinct mitochondria
579
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(a) (b)
(c)
Fig. 3. Mitochondrial morphology and ultrastructure of control- and patient-derived fibroblasts. (a) Representative images of mitochondrial
morphology of control and patients’ fibroblasts (P1, P2, P3 and P4). Cells labelled withMitoTracker®Red CM-H2Ros revealed two distinct phenotypes:
thread-like (control) and grain-like (P1, P2, P3 and P4), the latter associated with mitochondrial fission. (b) Quantification after MitoTracker®Red
CM-H2Ros label of the mitochondrial phenotypes observed in three independent experiments (each bar represents a minimum of 40 images containing
a minimum of 2–3 cells). The results represent the mean±SD of three independent experiments. (c) Representative electron micrographs of control-
and patient-derived fibroblasts. Healthy control mitochondria contained groups of parallel cristae, which often extended through the entire body of the
organelle and presented a dense mitochondrial matrix. On the contrary, cblBmitochondria had a distinct morphology indicating changes in mitochondria
structure. Bars: 200 nm.
morphology including a marked decrease in size, a
striking lack of cristae and a rarefaction of matrix density
compared to controls (Fig. 3c).
Discussion
The functional analysis data reported herein suggest
that the patient-associated changes p.His183Leu and
p.Arg190dup are destabilizing mutations. Both changes
were associated with reduced ATR stability and half-life,
as described for other cblB mutations such as p.Ile96Thr
and p.Arg191Trp (4). p.Arg190dup is a severely destabi-
lizing mutation with concomitant greatly reduced ATR
activity; p.His183Leu has a milder effect. The results
suggest that p.His183Leu might be a misfolding muta-
tion with low residual activity in bacterial crude extract;
the purified mutant enzyme exhibits a specific activity,
KM
ATP and KM
OHCbl values that are within the wild-type
range.
Other evidence suggest that p.His183Leu and p.Arg
190dup are folding mutations including the [14C]-
propionate incorporation results under basal and stress
conditions. While P1 showed lower propionate uptake
than the controls under basal conditions, P2 cells only
showed a propionate pathway defect. The present results
are consistent with the idea that protein instability
under physiological stress is indicative of a high risk
of metabolic decompensation during illness, especially
when fever is present, as described (14). Differences in
the propionate pathway in P1 and P2 cells are probably
explained by changes in the expression of proteins
involved in the protein quality control system.
In all patient-derived fibroblasts, ROS content, the
bioenergetic profile and mitochondrial structure were
markedly different compared to those of control cells.
The mitochondrial reserve capacity of the patients’
fibroblasts was reduced, a problem known to occur in
short-chain acyl-CoA dehydrogenase disorder (SCAD)
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in the presence of destabilizing mutations (15). More-
over, the present results reflect significant differences in
clinical outcome between siblings with the same geno-
type; P2 and P4, who had better clinical outcomes than
their respectively siblings P1 and P3, appeared to suffer
less mitochondrial dysfunction.
Grain-like structures have been related to mitochon-
drial fission, a mechanism involved in the maintenance
of mitochondrial function and the preservation of the
mitochondrial genome, but also in pre-apoptotic events
(16). These grain-like structures were observed in all
four patient-derived fibroblasts. The marked structural
modification we report in cblB mitochondria may be
correlated with a decrease in the efficiency of oxygen
reduction and ATP generation and an increase in ROS
production. In addition, laminar bodies and autophago-
somes engulfing mitochondria were observed in cblB
cells suggesting that autophagy is characterized by a
selective mitophagy. These promising results will be
followed up with further studies.
The improvement of mitochondrial dysfunction has
been proposed as a new therapeutic goal in several
human disorders. Treatment of these pathologies is
not straightforward, but would probably involve com-
binations of conventional and novel pharmacological
treatments plus nutritional interventions, including the
possible consumption of antioxidants to reduce the ROS
content in specific tissues and organs (17).
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